Transcleral or endoscopic cyclophotocoagulation support glaucoma therapy
April 1st 2012Results from a retrospective review of outcomes after transcleral or endoscopic cyclophotocoagulation for a variety of glaucoma conditions provide additional information on the efficacy and safety of these procedures, including in select subgroups composed of eyes with either neovascular glaucoma or better than count fingers vision.
Lens now has better safety profile
April 1st 2012Data from patients with the V4 model of the posterior chamber, foldable collagen copolymer phakic IOL implanted show that it provides excellent refractive and visual results, and, thanks to design modifications, a safety profile that is favorable, at least over the short term.
Bausch + Lomb acquires ISTA Pharmaceuticals
March 28th 2012Bausch + Lomb has signed a definitive agreement to acquire ISTA Pharmaceuticals for $9.10 per share in cash, or a total of approximately $500 million. The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the second quarter of 2012.
Study results tend to favor WFG for hyperopic LASIK
March 28th 2012Early results from a pilot study comparing wavefront-guided (WFG) and wavefront-optimized (WFO) techniques for hyperopic LASIK show excellent safety and predictability for both, but also some differences between groups that consistently favor the WFG procedure, reported co-investigators Anthony C. Liu, MD, and Edward E. Manche, MD.
Anterior segment module receives FDA clearance
March 28th 2012Heidelberg Engineering GmbH has been granted FDA clearance for a module that enhances its proprietary spectral-domain optical coherence tomography (OCT) platform by providing a detailed, multi-modality view of the anterior segment (Spectralis Anterior Segment Module).
Russia implements pediatric imaging program
March 28th 2012Clarity Medical Systems Inc. has announced the implementation of a significant program using its proprietary pediatric wide-field digital imaging system (RetCam) in the Russian Federation. The digital imaging system is used to create high-quality digital images of the exterior and interior of infant eyes to determine if infants have pediatric ocular diseases.
PRK found safer than LASIK for RK re-treatments
March 21st 2012Conventional LASIK and wavefront-guided PRK produced similar visual results compared with conventional PRK when performed to enhance RK procedures. LASIK, however, was associated with substantially more complications, said John Cason, MD, who presented the findings of the RK Re-treatment Study.
Alcon, ThromboGenics market ocriplasmin
March 21st 2012Alcon Laboratories plans to introduce ocriplasmin in more than 40 countries worldwide under the terms of a new agreement with ThromboGenics that lets it commercialize the truncated form of the human serine protease plasmin in all markets outside the United States.
IAPB general assembly set for September
March 21st 2012“Eye Health: Everyone's Business” will be the theme of the ninth general assembly of the International Agency for the Prevention of Blindness, which will be held Sept. 17 to 20 in Hyderabad, India. All ophthalmologists, optometrists, and other eye-care service providers and health-care professionals are invited.
Game controllers help identify torticollis
March 21st 2012Remotes for the Nintendo Wii gaming system have been known to do everything from sharpen a player’s tennis skills to help rid the world of zombies. So perhaps it’s not surprising that they can also help identify children who have ocular torticollis.
OT wins Neal Award for Best News Coverage
March 21st 2012Ophthalmology Times was awarded Best News Coverage status at the 58th annual Jesse H. Neal National Business Journalism Awards competition recognizing editorial excellence. The awards were announced and presented March 16 at a ceremony at the Mandarin Oriental in New York City.
Acadia, Allergan extend drug discovery collaboration
March 21st 2012Acadia Pharmaceuticals Inc. and Allergan Inc. will continue to collaborate on drug discovery and development of new therapeutics for glaucoma and other ophthalmic indications through March 2013 under the terms of an extension that adds a year to the research term originally established in March 2003.